Quantitative Measurement of Communication Ability in Children with Angelman Syndrome
Summary by Allyson Berent, DVM, DACVIM Individuals affected with Angelman syndrome (AS) are known to have limited functional speech and are typically able to communicate through gestures, sounds, minimal signs, and augmentative communication devices (AAC). The lack of functional speech in AS is thought to be associated with cognitive delays and oral motor dysfunction. Traditional […]
FAST US and FAST AU Announce Joint Funding To Dr. Arthur Beaudet To Generate Mouse Lines Expressing Human UBE3A Antisense
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (aka a cure).”~Dr. Arthur Beaudet The Foundation for Angelman Syndrome Therapeutics (FAST) US and FAST AU are excited to announce joint funding to Dr. Beaudet to generate mouse lines expressing human UBE3A […]
Towards Therapeutics – The FIRE Team Series, Part I
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Florida Health Byrd Alzheimer Institute. Dr. Weeber also serves on the Foundation for Angelman Syndrome Therapeutic’s (FAST) Scientific Advisory Board and the FAST Integrative Research Environment (FIRE) Initiative. The FIRE […]
Collaborating for Clinical Trials
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome community has reached one of the most significant advancements in the field of Angelman Syndrome (AS) to date: representatives from six pharmaceutical companies, scientists, clinicians, therapists, parents, private industry, the Foundation for […]
The FIRE team of FAST turns on Ube3a in mice with Angelman Syndrome….the future gets even MORE promising with Zinc Finger technology.
Read about the recently published paper “Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain”. The future gets even more promising with Zinc Finger technology.
Moms Rock!!!!
On May 11th in Castle Rock, Colorado, approximately 400 participants came out for the first-ever “Moms Rock 5K” for FAST! A virtual run was also held with several angel families lacing up for their own race. Runners and walkers enjoyed some awesome Colorado spring weather, a great silent auction with a ton of amazing items donated […]
Thank You…
Did you know that the Angelman community is the driving force behind research into treatments and a cure for Angelman Syndrome? Did you know that the Angelman community, single handedly, funded both the research on and the clinical trial for Minocycline as a Treatment for Angelman Syndrome? Did you know that the Angelman community has […]
Uncharted Waters – An Update From FAST On The Minocycline Clinical Trial
In March of 2013, the Tampa 24, wrapped up their final visits to Tampa General Hospital for the human clinical trial to test the efficacy of minocycline in treating symptoms of Angelman Syndrome (AS). The “Tampa 24” is the name penned by the Angelman community for the 24 children randomly chosen to participate in the […]
FAST Announces The 2nd Annual Global Summit on Angelman Syndrome
The Foundation for Angelman Syndrome Therapeutics (“FAST”) is pleased to announce that the 2nd Annual Global Summit on Angelman Syndrome will take place on Saturday and Sunday, December 7-8, 2013 at the Hyatt Regency Chicago. You will not want to miss this year’s excitement as we have more free seminars, more guest speakers and even […]
Lite the Night on FIRE, a benefit for FAST
Please join us for a unique fundraising event on Friday, Sept. 11th, 2015 at Boston Harbor Hotel from 7:00-11:30pm. Enjoy great food & drinks, dancing to the band Fusion, guest speakers, silent auction, and inspiring “Lite the Night” paddle raise. FAST is committed to raising at least $20 million to continue support of the FIRE […]